On October 14, 2025, Artivion announced at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting that its AMDS PERSEVERE and PROTECT clinical trials demonstrated high rates of organ perfusion improvement and favorable safety profiles in patients with acute aortic dissection following AMDS implantation.
The data from both trials provide critical evidence that supports Artivion’s premarket approval application to the U.S. Food and Drug Administration for its hybrid prosthesis device, the AMDS.
The announcement marks a significant milestone for Artivion, strengthening the clinical foundation for the AMDS and advancing the company’s strategy to bring the device to market in the United States.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.